$168 million BARDA contract for ModeX for next-gen COVID-19 program

2 October 2023

ModeX Therapeutics, an OPKO Health (Nasdaq: OPK) company, has received a sizeable grant of up to $168 million from the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Administration for Strategic Preparedness and Response at the US Department of Health and Human Services.

The BARDA contract includes an initial $59 million for the development, manufacturing, and execution of a Phase I clinical trial for a next-generation MSTAR multi-specific antibody with broad neutralizing activity against known variants of SARS-CoV-2.

This comes on the heels of other recently announced BARDA contracts as the government looks for proactive ways to address public health threats, and ModeX is one of the first companies to receive funding for a next-gen COVID program.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK